HGF/c-MET pathway in cancer: from molecular characterization to clinical evidence
J Fu, X Su, Z Li, L Deng, X Liu, X Feng, J Peng - Oncogene, 2021 - nature.com
This review provides a comprehensive landscape of HGF/c-MET (hepatocyte growth factor
(HGF)/mesenchymal–epithelial transition factor (c-MET)) signaling pathway in cancers. First …
(HGF)/mesenchymal–epithelial transition factor (c-MET)) signaling pathway in cancers. First …
Lung cancer: Biology and treatment options
H Lemjabbar-Alaoui, OUI Hassan, YW Yang… - … et Biophysica Acta (BBA …, 2015 - Elsevier
Lung cancer remains the leading cause of cancer mortality in men and women in the US
and worldwide. About 90% of lung cancer cases are caused by smoking and the use of …
and worldwide. About 90% of lung cancer cases are caused by smoking and the use of …
[HTML][HTML] First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
Background The efficacy of the ALK inhibitor crizotinib as compared with standard
chemotherapy as first-line treatment for advanced ALK-positive non–small-cell lung cancer …
chemotherapy as first-line treatment for advanced ALK-positive non–small-cell lung cancer …
[HTML][HTML] Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): a hybridization capture-based next-generation …
The identification of specific genetic alterations as key oncogenic drivers and the
development of targeted therapies are together transforming clinical oncology and creating …
development of targeted therapies are together transforming clinical oncology and creating …
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES) …
A Sartore-Bianchi, L Trusolino, C Martino… - The Lancet …, 2016 - thelancet.com
Background We previously found that dual HER2 blockade with trastuzumab and lapatinib
led to inhibition of tumour growth in patient-derived xenografts of HER2-amplified metastatic …
led to inhibition of tumour growth in patient-derived xenografts of HER2-amplified metastatic …
Genetic landscape and biomarkers of hepatocellular carcinoma
Hepatocellular carcinoma (HCC) has emerged as a major cause of cancer-related death. Its
mortality has increased in Western populations, with a minority of patients diagnosed at …
mortality has increased in Western populations, with a minority of patients diagnosed at …
Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of …
C Le Tourneau, JP Delord, A Gonçalves… - The lancet …, 2015 - thelancet.com
Background Molecularly targeted agents have been reported to have anti-tumour activity for
patients whose tumours harbour the matching molecular alteration. These results have led …
patients whose tumours harbour the matching molecular alteration. These results have led …
Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?
The traditional approach to the treatment of patients with advanced-stage non-small-cell
lung carcinoma (NSCLC) harbouring ALK rearrangements or EGFR mutations has been the …
lung carcinoma (NSCLC) harbouring ALK rearrangements or EGFR mutations has been the …
Targeting ALK: precision medicine takes on drug resistance
JJ Lin, GJ Riely, AT Shaw - Cancer discovery, 2017 - AACR
Anaplastic lymphoma kinase (ALK) is a validated molecular target in several ALK-
rearranged malignancies, including non–small cell lung cancer. However, the clinical …
rearranged malignancies, including non–small cell lung cancer. However, the clinical …
Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
Background Chromosomal rearrangements of the gene encoding ROS1 proto-oncogene
receptor tyrosine kinase (ROS1) define a distinct molecular subgroup of non–small-cell lung …
receptor tyrosine kinase (ROS1) define a distinct molecular subgroup of non–small-cell lung …